Three different skin complaints
The label sorts skin problems on Zepbound® into separate rows, and it helps to know which one you have.
- Rash where you injected. Injection site rash is one of the terms inside the injection site reaction row, reported by 6% to 8% on Zepbound® and 2% on placebo [1]. That is covered in detail on the injection site page.
- Rash or hives elsewhere. Itchy patches, hives or a spreading rash away from the injection site fall under hypersensitivity reactions, the allergic-type row this page focuses on [1].
- Skin that hurts or burns without a rash. The label lists dysesthesia, an unpleasant or abnormal skin sensation, as a separate, uncommon finding [1].
Allergic-type reactions by dose
Table 1 in the US label combines two 72-week trials, SURMOUNT-1 (no diabetes) and SURMOUNT-2 (type 2 diabetes); its 5 mg column comes from SURMOUNT-1 alone [3]. Hypersensitivity reactions were reported at the same rate on every dose [1]. Canada gives patient counts and splits the reactions by when they began, and Europe, where tirzepatide is sold as Mounjaro®, classes them as common [3][4].
| Source | Zepbound® 5 mg | 10 mg | 15 mg | Placebo |
|---|---|---|---|---|
| US label, Table 1: hypersensitivity reactions [1] | 5% | 5% | 5% | 3% |
| Canadian monograph, Table 2: hypersensitivity reactions (patients) [3] | 31 (4.9%) | 47 (5.0%) | 51 (5.4%) | 30 (3.1%) |
| Canada: reactions within 24 hours of a dose [3] | 1.8% | 2.4% | 2.1% | 0.4% |
| Canada: reactions after 24 hours, before the next dose [3] | 3.5% | 3.2% | 3.8% | 2.7% |
| US label: dysesthesia [1] | 0.2% | 0.2% | 0.4% | 0.1% |
| EU, tirzepatide as Mounjaro®: weight-management and sleep apnea pools [4] | 5.0% vs 3.8% (weight) and 3.0% vs 2.1% (sleep apnea); common |
Timing, antibodies and severity
The timing split is the clearest Zepbound®-specific signal. Reactions starting within a day of an injection occurred in 2.1% on Zepbound® against 0.4% on placebo, while reactions that began later, but before the next weekly dose, were much closer to placebo (3.5% against 2.7%) [1][3]. A rash that appears within hours of an injection, especially more than once, is therefore worth reporting even if it settles.
Antibodies to tirzepatide are common: they were detected in 64.5% of people in the weight trials and 60.6% in the sleep apnea trials, with no clinically significant effect on how well Zepbound® worked [1]. Allergic-type reactions were more frequent in people with antibodies (6.2%) than without (3%) [1]. Across four SURMOUNT trials, Canada reports 5.5% against 3.0% [3].
Severe reactions were rare: 0.1% on Zepbound® and none on placebo in the weight trials, with similar rates in the sleep apnea trials [1]. After approval, anaphylaxis and angioedema have been reported with tirzepatide [1]. Zepbound® must not be used after a serious allergic reaction to tirzepatide or to any of its ingredients, and the label asks for caution in people who had angioedema or anaphylaxis with another GLP-1 medicine, because it is unknown whether they are more prone to such reactions [1].
What differs between pens and vials
In the US, Zepbound® comes as a single-dose pen, a single-dose vial, a multi-dose vial and a single-patient-use KwikPen [1]. The single-dose forms contain tirzepatide with sodium chloride, sodium phosphate and water; the multi-dose vial and KwikPen add benzyl alcohol, glycerin and phenol as part of a preserved formulation [1]. In Canada, the KwikPen is the only presentation [3].
Canada’s monograph says benzyl alcohol may cause allergic reactions and lists it, by name, among the ingredients that rule out using Zepbound® in someone who is hypersensitive to them [3]. If a rash starts after you change presentation, say so, and note which one you were using. The US label asks prescribers to make sure patients are trained again whenever their presentation changes [1].
Reports from outside the trials
Single-patient case reports add detail but cannot show how often something happens. One 2026 report describes a 37-year-old woman who developed hives, facial swelling, wheezing and low blood pressure soon after her first known tirzepatide dose, needed two adrenaline injections, and had a possible second wave of symptoms about an hour later; allergy testing was not done, so the mechanism stayed unclear [5]. An earlier report describes widespread itching and hives after a first dose in a woman with type 2 diabetes, which settled with antihistamines [6].
Skin pain without a rash has also been described. A 2026 case series reports two people with severe obesity taking tirzepatide for weight management who developed allodynia, pain from touch that should not hurt; it appeared with dose increases and resolved after stopping [7]. An analysis of the WHO VigiBase database linked tirzepatide reports with heightened skin sensitivity; spontaneous reports show association, not cause [8]. At the level of whole trial programmes, a 2026 meta-analysis of GLP-1 medicines found injection site reactions clearly more frequent than with comparators, while rashes and other skin events elsewhere were rare and not significantly increased [9].
Rashes with other causes
MedlinePlus notes that many rashes come from dermatitis, often contact dermatitis from something touching the skin: chemicals in elastic, latex or rubber, cosmetics, soaps and detergents, or dyes in clothing [10]. Eczema, psoriasis, seborrheic dermatitis, shingles, insect bites, infections and other medicines are further causes, and sometimes no cause is found [10].
Hives in particular have many triggers besides medicines: foods such as shellfish, nuts, eggs and milk, pollen, animal dander, insect bites, infections, stress, heat, cold, sweating and exercise [11]. Individual welts usually change shape and fade within hours, and one lasting longer than 48 hours is unusual [11]. New soaps, lotions or laundry products around the time of an injection are worth writing down.
Gentle care for a mild rash
For a simple rash, MedlinePlus suggests gentle cleansers, warm rather than hot water, patting the skin dry instead of rubbing, leaving the area uncovered where possible, and stopping any newly added cosmetic or lotion [10]. For mild hives it advises avoiding hot baths and tight clothing, and says a provider may suggest an antihistamine; ask your pharmacist or prescriber which one suits you [11].
MedlinePlus also asks you not to stop or change any medicine without talking to your provider first [10]. That advice has one clear exception on Zepbound®: signs of a serious allergic reaction mean stopping the medicine and getting help straight away [2].
Zepbound®, KwikPen® and Mounjaro® are registered trademarks of Eli Lilly and Company. PepLabo is not affiliated with or endorsed by Eli Lilly and Company.
When to get help
| Sign | Who to contact | How fast | Source |
|---|---|---|---|
| A very fast heartbeat, fainting, severe rash or itching, difficulty breathing or swallowing, or a swollen face, lips, tongue or throat | Stop Zepbound® and get emergency help (911 or local number) | Emergency | Medication Guide [2] |
| A tight throat or shortness of breath with any rash | Emergency services | Emergency | MedlinePlus [10] |
| Hives or a spreading itchy rash after a dose, without breathing problems | Contact your prescriber promptly; the label advises stopping Zepbound® if an allergic reaction occurs | Today | Label §5.6 and §17 [1] |
| Red streaks, swelling, warmth or very tender skin, or rash with fever | Your healthcare provider (possible infection) | Today | MedlinePlus [10] |
| Burning, tingling or painful skin without a visible rash | Mention it to your prescriber | At your next appointment | Canadian patient information [3] |
| A rash that keeps returning at injection sites | Discuss at your next appointment | At your next appointment | Label §6.1 [1] |
